LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib

NCT01085136 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1154

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Investigator´s choice of chemotherapy
DRUG: BIBW 2992

Sponsor

Boehringer Ingelheim